HK Stock Market Move | LEAPMOTOR (09863) continues to rise by more than 3%, with over 50,000 deliveries in March leading the new forces in car manufacturing. The flagship model D19 is set to be launched soon.
Lingpao Auto (09863) rose more than 3% again, as of the time of filing, it increased by 3.02% to 52.8 Hong Kong dollars, with a turnover of 4.02 billion Hong Kong dollars.
LEAPMOTOR (09863) rose by over 3%, as of the time of writing, up by 3.02% at 52.8 Hong Kong dollars, with a turnover of 4.02 billion Hong Kong dollars.
On the news front, LEAPMOTOR delivered 50,029 units in March, once again becoming the monthly sales champion among new carmakers, with a year-on-year increase of 35% and a month-on-month increase of about 78.25%. LEAPMOTOR revealed that it will unveil the Lafa5 Ultra model at the Beijing Auto Show this month. In addition, the flagship D19 model will be launched on April 16. Recently, LEAPMOTOR also announced that LEAPMOTOR founder, Chairman and CEO Zhu Jiangming, as well as shareholder Fu Liquan, have increased their holdings in the company again, at an average price of about 45.1 Hong Kong dollars, with a total increase of approximately 2.3 billion Hong Kong dollars, to demonstrate confidence in the company's development.
Related Articles

China Securities Co., Ltd. reviews the A-share market in the first quarter of 2026: This bull market is more forward-looking in terms of regulation and will take timely measures to address overheated trading.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.
China Securities Co., Ltd. reviews the A-share market in the first quarter of 2026: This bull market is more forward-looking in terms of regulation and will take timely measures to address overheated trading.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.

RECOMMEND

Hong Kong Stocks Surge! Buying Opportunity Or Wait And See? Analysts Provide Comprehensive Interpretation
02/04/2026

Narrative Drives Everything As China’s AI Newcomers Enter An Era Of Extreme Volatility, Retail Investors Flood In
02/04/2026

Fund Cohort Stocks Rally As Institutional Confidence In Hong Kong Equities Shows Signs Of Repair
02/04/2026


